SCHEMBL18980952

SCHEMBL18980952

Cc1ccc(S(=O)(=O)NC(c2ccc(F)cc2)c2ccc(Cl)cc2)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
UTS2R Q9UKP6 1/20 0.54
LMNA P02545 4/20 0.48
TP53 P04637 3/20 0.48
KMT2A Q03164 3/20 0.48
HTT P42858 2/20 0.48
MAPT P10636 2/20 0.48
S1PR1 P21453 1/20 0.45
GAA P10253 2/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
EGFR P00533 4/20 0.44
ERBB2 P04626 4/20 0.44
CA12 O43570 2/20 0.44
CA2 P00918 2/20 0.44
CA9 Q16790 2/20 0.44
CA14 Q9ULX7 2/20 0.44
ALDH1A1 P00352 1/20 0.44
CA1 P00915 1/20 0.44
CA3 P07451 1/20 0.44
CA4 P22748 1/20 0.44
CA6 P23280 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18980950 1.00 UTS2R (0.54) UTS2RLMNATP53KMT2AHTT
SCHEMBL19010046 0.93 GAA (0.50) LMNATP53KMT2AHTTMAPT
SCHEMBL18980948 0.87 MAPT (0.56) UTS2RLMNATP53KMT2AMAPT
SCHEMBL18980585 0.87 ALDH1A1 (0.50) LMNATP53KMT2AHTTGAA
SCHEMBL29740753 0.87 MAPT (0.56) UTS2RLMNATP53KMT2AMAPT
SCHEMBL18980705 0.83 CNR1 (0.54) UTS2RLMNATP53KMT2AEGFR
SCHEMBL18980854 0.83 CNR1 (0.54) KMT2AEGFRERBB2CA12CA2
SCHEMBL18980703 0.83 CNR1 (0.54) UTS2RLMNATP53KMT2AEGFR
SCHEMBL28420194 0.79 CNR1 (0.54) LMNATP53KMT2AHTTGAA
SCHEMBL15871417 0.79 ALDH1A1 (0.56) LMNAKMT2AGAAL3MBTL1CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10118169-B2 Chiral ligand-based metal-organic frameworks for broad-scope asymmetric catalysis THE UNIVERSITY OF CHICAGO (US) 2018-11-06 US disclosed
US-20170173572-A1 CHIRAL LIGAND-BASED METAL-ORGANIC FRAMEWORKS FOR BROAD-SCOPE ASYMMETRIC CATALYSIS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2017-06-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170173572-A1 CHIRAL LIGAND-BASED METAL-ORGANIC FRAMEWORKS FOR BROAD-SCOPE ASYMMETRIC CATALYSIS POF1B, FGFR1, COASY UTS2R 3671/4885LMNA 3689/4885TP53 4050/4885
US-10118169-B2 Chiral ligand-based metal-organic frameworks for broad-scope asymmetric catalysis POF1B, FGFR1, COASY UTS2R 3671/4885LMNA 3689/4885TP53 4050/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.